Multiple Myeloma

OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.

ISB 2001 has received fast track designation from the FDA for patients with relapsed or refractory multiple myeloma who received 3 or more prior therapies.

The top 5 OncLive videos of the week cover insights in colorectal cancer, prostate cancer, myeloma, renal cell carcinoma, and urothelial carcinoma.

David S. Siegel, MD, explains the rationale for assessing mezigdomide—a novel thalidomide derivative—in relapsed/refractory multiple myeloma.

Amin Sobh, PhD, discusses findings from a study investigating the immune surveillance–modulating capabilities of NSD2 overexpression in multiple myeloma.

Linvoseltamab earned EC approval for relapsed/refractory multiple myeloma after at least 3 prior lines of therapy.

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

A multicenter review comparing ide-cel and cilta-cel in relapsed/refractory multiple myeloma showed better survival with cilta-cel but increased toxicity.

Janine Joseph, MS, MBA, discusses the current state of research and future directions for resistance training interventions in patients with multiple myeloma.

Kiavasch Mohammad Nejad Farid, MD, discusses 2 planned investigations of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and AL amyloidosis.

Salvage transplant was not associated with long-term survival benefits in relapsed/refractory multiple myeloma.

Alfred L. Garfall, MD, MS, discusses the rationale of the phase 2 BMT CTN 1902 trial in multiple myeloma.

Michael R. Bishop, MD, explains the rationale for assessing the CAR T-cell therapy anito-cel in relapsed/refractory multiple myeloma.

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, myelofibrosis, breast cancer, and sarcoma.

María-Victoria Mateos, MD, PhD, discusses data from the long-term update of CARTITUDE-4 she presented during the 51st Annual EBMT Meeting.

Jeffrey Zonder, MD, discusses the need for increased screening for patients who are at higher risk of developing multiple myeloma.

Paul G. Richardson, MD, discusses 2 quadruplet regimens for the treatment of patients with newly diagnosed multiple myeloma and changes in administration.

Two belantamab mafodotin–based combinations have been approved in the United Kingdom for relapsed/refractory multiple myeloma.

Kiavasch Mohammad Nejad Farid, MD, discusses how compassionate use of MDC-CAR-BCMA001 could address unmet needs for multiple myeloma and AL amyloidosis.

Joshua Richter, MD, discusses the identification of early abnormalities that may indicate that a patient has multiple myeloma.

María-Victoria Mateos, MD, PhD, discusses the future clinical development of ciltacabtagene autoleucel in multiple myeloma.

Daratumumab plus lenalidomide maintenance improved clinical outcomes vs lenalidomide monotherapy in multiple myeloma after transplant.

D-VRd has the potential to significantly improve clinical outcomes in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma.

Treatment with cilta-cel led to improvements across several QOL subscales compared with SOC therapy in patients with lenalidomide-refractory myeloma.

Daratumumab reduced the risk of disease progression or death vs active monitoring in high-risk smoldering multiple myeloma.